Aethlon Medical biz Exosome Science readies CTE biomarker trial of ex-NFL players

The objective of our Exosome Sciences subsidiary is to further reinforce the clinical observations that resulted from our first study in former NFL players and then translate these outcomes into functional products that help those at risk of suffering from CTE and potentially other neurological disorders that involve the abnormal aggregation of Tau protein in the brain,” Aethlon Medical CEO Jim Joyce said in a prepared statement. Sample collection in the study is being conducted in collaboration with Translational Genomics Research Institute’s Center for Noninvasive Diagnostics co-director Dr. Kendall Van Keuren-Jensen, the company said. “Since our announcement of plans for the study earlier this year, we have received an overwhelming response from former NFL players and their family members. Researchers at TGen will use these samples to study extracellular RNAs, which may be useful for monitoring the central nervous system,” Dr. Van Keuren-Jensen said in prepared remarks. The post Aethlon Medical biz Exosome Science readies CTE biomarker trial of ex-NFL players appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Neurological Aethlon Medical Inc. Exosome Sciences Source Type: news